0.00Open0.05Pre Close0 Volume84 Open Interest2.50Strike Price0.00Turnover87.21%IV25.00%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2148Delta0.6449Gamma40.80Leverage Ratio-0.0029Theta0.0003Rho8.77Eff Leverage0.0015Vega
LAVA Therapeutics Stock Discussion
LAVA Therapeutics N.V., a leader in the biotechnology sector, has recently announced a significant clinical development milestone achieved by Pfizer for the drug PF-08046052. This milestone has prompted the first payment of $7 million to LAVA, marking a notable event in the field of immuno-oncology. $LAVA Therapeutics(LVTX.US)$
https://stockregion.app/p/biotech-leader-announces-7m-milestone
No comment yet